A batch of blood pressure pills failed a basic lab test, and now 13,567 bottles are off the market nationwide.
Quick Take
- The Food and Drug Administration (FDA) lists recall number D-0610-2026 for chlorthalidone tablets that failed dissolution testing.
- The affected product is 25-milligram chlorthalidone, 100-tablet bottles, batch RISA24002, expiring April 2027.
- Manufacturer Inventia Healthcare Limited voluntarily pulled the batch on September 3, 2026, before the FDA classified it on September 17.
- This marks the second dissolution-related recall from the same manufacturer this year, following a June recall of 11,460 bottles.
What The FDA Record Actually Shows
The FDA’s enforcement database spells it out plainly: recall D-0610-2026 covers chlorthalidone tablets that failed dissolution specifications. That means the pills didn’t break down the way they’re supposed to once swallowed. Dissolution testing checks whether a tablet releases its active ingredient properly in the body. When it fails, the drug may not work as intended.
The recalled lot is specific and traceable. It’s 25-milligram chlorthalidone in 100-tablet bottles, labeled with National Drug Code 64980-599-01, from batch RISA24002, set to expire in April 2027. Inventia Healthcare Limited, the manufacturer, distributed the bottles nationwide. The FDA reports 13,567 bottles were caught up in the recall.
Why The Risk Level Matters For Patients
The FDA classified this as a Class II recall on September 17, 2026. That label matters. Class II means the product could cause temporary or reversible health problems, with only a remote chance of something serious. It is not the agency’s top-tier warning reserved for life-threatening defects.
Inventia didn’t wait for federal orders. The company voluntarily initiated the recall on September 3, 2026, two weeks before the FDA formally classified it. That sequence shows the manufacturer caught the problem through its own testing and moved before regulators forced the issue.
Thousands of blood pressure medication bottles recalled nationwide after pills fail quality test https://t.co/vd0IRsT1NF pic.twitter.com/ue5236EBBA
— New York Post (@nypost) November 3, 2026
A Repeat Problem From The Same Manufacturer
This isn’t Inventia’s first dissolution stumble this year. In June 2026, the company voluntarily recalled 11,460 bottles from batches RISA24001 and RISB24002 for the same reason: failed dissolution specifications. Two separate recalls tied to the same quality defect within a few months raise fair questions about the company’s manufacturing controls.
Dissolution failures aren’t rare in the drug industry, but they’re far from trivial either. The FDA’s own fiscal year 2024 quality report found dissolution failures accounted for 36 percent of all failed-specification recalls, trailing only chemical impurity problems. That context shows regulators watch this type of defect closely across the entire pharmaceutical supply chain, not just for this one manufacturer.
Chlorthalidone’s Role And Why Reduced Effectiveness Matters
Chlorthalidone is a widely prescribed diuretic used to treat high blood pressure. Millions of Americans rely on it daily to keep their numbers in check and lower their risk of stroke and heart attack. A pill that doesn’t dissolve correctly may not deliver the full dose, which could leave blood pressure less controlled than a patient and their doctor expect.
The practical advice from health reporting on this recall is consistent: patients should not stop taking chlorthalidone on their own. Quitting a blood pressure medication abruptly carries its own risks. Anyone with the recalled bottle should check the lot number against batch RISA24002 and talk to their pharmacist or doctor about next steps.
What Comes Next For Oversight
Inventia Healthcare Limited is based in India, and its products reach pharmacy shelves across the United States. That global supply chain is standard practice in today’s generic drug market. Still, a second dissolution failure in one year gives regulators reason to look harder at the company’s production line.
For now, the facts are straightforward. A specific batch failed a specific test, a company pulled it fast, and federal regulators logged the risk as moderate rather than severe. Patients holding the affected bottles have a clear, documented product to check and a clear path forward: call your pharmacist before you do anything else.
Sources:
foxbusiness.com, api.fda.gov, goodhousekeeping.com, dallasnews.com, health.com, aarp.org
